-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There were an estimated 18.
1810 960
In recent years, the occurrence of venous thrombosis during systemic chemotherapy has become a research hotspot
In order to better understand the mechanism of CAT and take effective treatment measures, this study explored the feasibility of continuing chemotherapy and concurrent anticoagulation in consideration of drug interactions
research method
research methodWe retrospectively evaluated cancer patients who developed gastrointestinal CAT from February 2017 to December 2020 at Gifu University Hospital Affiliated to the Faculty of Medicine, Japan
Research result
Research resultWe monitored CAT in 117 edoxaban-treated patients with gastrointestinal cancer from February 2017 to December 2020
Table 1.
Table 1.
Figure 1.
Figure 1.
Figure 2.
Figure 2.
According to the dose reduction criteria, 82 patients (71.
Figure 3.
Figure 3.
Analysis conclusion
Analysis conclusionThe incidence of CAT in patients with gastrointestinal cancer in the study is not low.
Original source:
Original source:Tanaka Y, Sato Y, Suetsugu T, et al.
Tanaka Y, Sato Y, Suetsugu T, et al.
Treatment Strategy for Cancer-associated Venous Thromboembolism During Chemotherapy: The Keep ACT2 Concept.
Cancer Diagn Progn.
2021 Nov 3;1(5):417-422.
doi: 10.
21873/cdp .
10055.
PMID: 35403169; PMCID: PMC8962864.
Leave a message here
